文献速递放疗物理与技术

利用切伦科夫光激活光疗增强放射治疗

Enhancing Radiation Therapy Through Cherenkov Light-Activated Phototherapy.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2017-11-16

本研究提出以兆伏级光子束产生的切伦科夫光激活光疗药物(RECA)来增强放疗,聚焦于补骨脂素。体外实验显示RECA较单纯放疗加补骨脂素可提高细胞毒性并显著增加MHC I表面表达,首次证明临床治疗束产生的切伦科夫光可原位激活补骨脂素。

要点

  • RECA在2 Gy/6 MV下使4T1和B16细胞细胞毒性分别提高达20%和9.5%。
  • RECA在3 Gy和6 Gy下使MHC I中位表达分别提高约450%和250%(P << .0001)。
  • B16克隆形成实验在6 Gy和12 Gy下细胞存活分别降低7%(P = .017)和36%(P = .006)。

核心结论

  • 首次证明临床兆伏级治疗束产生的切伦科夫光可原位激活补骨脂素,即RECA策略具有可行性。

研究设计与样本

  • 体外研究,使用B16黑色素瘤和4T1小鼠乳腺癌细胞,比较放疗加RECA与单纯放疗的细胞毒性和MHC I表达。
  • 细胞毒性检测包括发光法和克隆形成法,MHC I检测采用流式细胞术,并测量切伦科夫光强度。

主要发现

  • 发光法显示RECA(6 MV下2 Gy)较放疗加补骨脂素(切伦科夫光被阻断)使4T1和B16细胞细胞毒性分别提高达20%和9.5%。
  • 流式细胞术显示RECA处理细胞MHC I中位表达显著高于对照,3 Gy和6 Gy下分别约450%和250%(P << .0001)。
  • B16克隆形成实验在6 Gy和12 Gy下,有切伦科夫光时细胞存活分别降低7%(P = .017)和36%(P = .006)。

临床怎么用

  • RECA有望将补骨脂素治疗从浅表扩展到深部病灶,并可能通过增加MHC I表达增强抗原呈递。

局限性

  • 证据仅来自B16和4T1细胞体外实验,尚未在体内或临床中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This work investigates a new approach to enhance radiotherapy through a photo therapeutic agent activated by Cherenkov light produced from the megavoltage photon beam. The process is termed Radiotherapy Enhanced with Cherenkov photo-Activation (RECA). RECA is compatible with various photo-therapeutics, but here we focus on use with psoralen, an ultraviolet activated therapeutic with extensive history of application in superficial and extracorporeal settings. RECA has potential to extend the scope of psoralen treatments beyond superficial to deep seated lesions. METHODS AND MATERIALS: In vitro studies in B16 melanoma and 4T1 murine breast cancer cells were performed to investigate the potential of RT plus RECA versus RT alone for increasing cytotoxicity (local control) and increasing surface expression of major histocompatibility complex I (MHC I). The latter represents potential for immune response amplification (increased antigen presentation), which has been observed in other psoralen therapies. Cytotoxicity assays included luminescence and clonogenics. The MHC I assays were performed using flow cytometry. In addition, Cherenkov light intensity measurements were performed to investigate the possibility of increasing the Cherenkov light intensity per unit dose from clinical megavoltage beams, to maximize psoralen activation. RESULTS: Luminescence assays showed that RECA treatment (2 Gy at 6 MV) increased cytotoxicity by up to 20% and 9.5% for 4T1 and B16 cells, respectively, compared with radiation and psoralen alone (ie, Cherenkov light was blocked). Similarly, flow cytometry revealed median MHC I expression was significantly higher in RECA-treated cells, compared with those receiving radiation and psoralen alone (approximately 450% and 250% at 3 Gy and 6 Gy, respectively, P << .0001). Clonogenic assays of B16 cells at doses of 6 Gy and 12 Gy showed decreases in tumor cell viability of 7% (P = .017) and 36% (P = .006), respectively, when Cherenkov was present. CONCLUSION: This work demonstrates for the first time the potential for photo-activation of psoralen directly in situ, from Cherenkov light generated by a clinical megavoltage treatment beam.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Yoon SW, Tsvankin V, Shrock Z, et al. Enhancing Radiation Therapy Through Cherenkov Light-Activated Phototherapy. Int J Radiat Oncol Biol Phys. 2017. PMID: 29413289. doi:10.1016/j.ijrobp.2017.11.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。